APPENDICURE

When David’s care team brought up appendix cancer genetic testing, it was not really about David. It was about our daughter, Kathleen.

David is 53. He was diagnosed with goblet cell appendiceal cancer. Dr. Shen suggested a germline genetic test, and the point was not to change David’s treatment tomorrow. The point was to find out whether there is something written into his DNA that he could have passed down. If you are sitting with a new diagnosis, or you have lived with one for years, this is a question worth understanding, so I want to walk through what I learned.

Two kinds of tests, and why the difference matters

There are two very different genetic tests in cancer, and people mix them up all the time.

• Tumor testing (somatic testing) looks at the DNA inside the cancer itself. It tells you about mutations the tumor picked up over time, and it can help guide treatment. It does not tell you what you were born with.
• Germline testing looks at the DNA you were born with, the copy that sits in every cell of your body. If something shows up here, you have carried it your whole life, and there is a chance you passed it to your children.

David has already had tumor testing. The germline test asks a separate question. Is there an inherited variant sitting underneath all of this?

What the research says about appendix cancer genetic testing

For a long time the assumption was that appendix cancer is not inherited. That assumption is being questioned.

In a study published in JAMA Oncology, Dr. Andreana Holowatyj and her team at Vanderbilt reviewed germline panel testing from 131 people with appendix cancer. About 1 in 10, or 11.5 percent, carried an inherited variant in a cancer susceptibility gene. When they narrowed the group to people whose appendix was their first and only tumor, the rate held at 10.8 percent. Four of those patients had Lynch syndrome, a known inherited condition that raises the risk of several cancers. The authors concluded that genetic counseling and panel testing should be offered to every appendix cancer patient, regardless of age or family history.

The honest part, carrying a variant is not the same as knowing the cause

This is where I have to be careful, because the easy headline would be wrong.

A 2023 study led by Dr. Michael Foote looked at 237 people with appendiceal adenocarcinoma. He found a similar rate of inherited variants. But when he compared each germline result against what the tumor was actually doing, he argued that many of those variants may be incidental. In plain terms, the variant is real, but it may not be the thing that caused the appendix cancer.

What gives me confidence in the careful version is who is saying it. Dr. Foote, who made the incidental argument, and Dr. Shen, who treats David, are both authors on the 2025 appendiceal cancer consensus guidelines. The people writing the rulebook hold the careful view. So the honest statement is this. Inherited variants show up in roughly 1 in 10 appendix cancer patients, testing is worth doing, and we should not overstate what a positive result proves about cause.

Why tumor testing does not replace a germline test

A fair question came up for us. David already had his tumor sequenced, so why test again?

Because the two tests answer different questions, and tumor testing misses inherited variants. The 2024 ASCO guideline on germline testing put a number on it. Tumor profiling misses up to about 10 percent of people who actually carry an inherited pathogenic variant. A clean tumor report does not mean your germline is clear.

What this means for families

If David carries an inherited variant, our daughter can be tested for that one specific thing. This is called cascade testing. With most inherited variants, a child has about a 50 percent chance of carrying it.

A positive result for her would not mean she is going to get cancer. It would mean she and her doctors know to watch, and to start screening earlier than they otherwise would. A negative result would take a worry off the table. Either way she ends up with information, and information is what lets you act early instead of late. That is the whole reason Dr. Shen raised it. At 53, the test changes very little for David. For a daughter in her twenties, it could change the timing of everything.

Where appendix cancer genetic testing stands today

Appendix cancer does not yet have its own dedicated germline testing rule the way breast and prostate cancer do. The direction, though, is clear. The peritoneal metastases consensus guidelines from the PSM Consortium say germline testing should be considered as indicated. Leading GI cancer experts are openly debating whether every GI cancer patient should be offered germline testing. And the largest appendix specific study we have recommends testing everyone. If your team has not raised it, you are allowed to ask.

What we decided

David is getting the germline test. Not because it will change his chemo, and not because we believe his cancer was inherited. We are doing it for the one person it could protect the most. If the result is negative, that is a gift to our daughter. If it is positive, it is a map she can use for the rest of her life.

If you want to help the wider community see patterns like this more clearly, adding your own history to our patient data registry is one of the most useful things you can do in ten minutes.

I am a patient advocate, not a doctor. I write this to help you ask sharper questions, not to replace the advice of your own care team.